AU2003241051A8 - Use of shp-1 for the therapy of asthma - Google Patents

Use of shp-1 for the therapy of asthma

Info

Publication number
AU2003241051A8
AU2003241051A8 AU2003241051A AU2003241051A AU2003241051A8 AU 2003241051 A8 AU2003241051 A8 AU 2003241051A8 AU 2003241051 A AU2003241051 A AU 2003241051A AU 2003241051 A AU2003241051 A AU 2003241051A AU 2003241051 A8 AU2003241051 A8 AU 2003241051A8
Authority
AU
Australia
Prior art keywords
shp
asthma
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003241051A
Other versions
AU2003241051A1 (en
Inventor
Kevin B Bacon
Ningshu Liu
Peter Reinemer
Christian Rohlff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Oxford Glycosciences UK Ltd
Original Assignee
Bayer AG
Oxford Glycosciences UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Oxford Glycosciences UK Ltd filed Critical Bayer AG
Publication of AU2003241051A8 publication Critical patent/AU2003241051A8/en
Publication of AU2003241051A1 publication Critical patent/AU2003241051A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003241051A 2002-06-18 2003-06-18 Use of shp-1 for the therapy of asthma Abandoned AU2003241051A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0213964.0 2002-06-18
GBGB0213964.0A GB0213964D0 (en) 2002-06-18 2002-06-18 Protein
PCT/GB2003/002611 WO2003105884A1 (en) 2002-06-18 2003-06-18 Use of shp-1 for the therapy of asthma

Publications (2)

Publication Number Publication Date
AU2003241051A8 true AU2003241051A8 (en) 2003-12-31
AU2003241051A1 AU2003241051A1 (en) 2003-12-31

Family

ID=9938785

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003241051A Abandoned AU2003241051A1 (en) 2002-06-18 2003-06-18 Use of shp-1 for the therapy of asthma

Country Status (3)

Country Link
AU (1) AU2003241051A1 (en)
GB (1) GB0213964D0 (en)
WO (1) WO2003105884A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223272D0 (en) * 2002-10-08 2002-11-13 Oxford Glycosciences Uk Ltd A protein involved in therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999054450A1 (en) * 1998-04-17 1999-10-28 Ortho-Mcneil Pharmaceutical Inc. Assay methods for modulators of hematopoietic cell phosphatase

Also Published As

Publication number Publication date
GB0213964D0 (en) 2002-07-31
WO2003105884A1 (en) 2003-12-24
AU2003241051A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
EP1572131A4 (en) Antibody therapy
AU2003217870A8 (en) Pini-modulating compounds and methods of use thereof
HK1086488A1 (en) Compound and use thereof for the treatment of cancer
IL174871A0 (en) Compounds for dual photodiagnosis and therapy
AU2003213673A8 (en) Pin1-modulating compounds and methods of use thereof
HRP20041029A2 (en) Therapeutic use of selcetive pde10 inhibitors
IL178816A0 (en) The treatment of childhood asthma
IL175351A0 (en) Methods of treating asthma
AU2003285091A8 (en) Interferon antagonists useful for the treatment of interferon related diseases
PT1530466E (en) Use of nintedanib for the treatment of lung fibrosis
GB0305150D0 (en) Use of therapeutic compounds
EP1527196A4 (en) Treatment for asthma or allergies
AU2003275056A8 (en) Novel lapacho compounds and methods of use thereof
PL375564A1 (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
GB0219660D0 (en) Therapeutic use
GB0207410D0 (en) Compounds and their therapeutic use
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
EP1545287A4 (en) Vasoregulating compounds and methods of their use
GB0210741D0 (en) Methods of therapy
AU2003269257A1 (en) Use of cap-1 for the therapy of asthma
AU2003241051A8 (en) Use of shp-1 for the therapy of asthma
GB0207409D0 (en) Benzofuran-2H-3-one compounds and their therapeutic use
ZA200606071B (en) Methods of treating asthma
EP1569928A4 (en) Therapeutic compounds and methods
AU2003227519A1 (en) The use of milnacipran for the treatment of tension-type headache

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 18, NO 8, PAGE(S) 2128 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME OXFORDGLYCOSCIENCES (UK) LTD, APPLICATION NO. 2003241051, UNDER INID (71) CORRECT THE NAME TO READ BAYER AG; HERATH, HERATH, MUDIYANSELAGE, ATHULA, CHANDRASIRI; OXFORD GLYCOSCIENCES (UK) LTD